Registrational assay menu
We offer a broad range of investigation ready assays supported in our CAP/CLIA lab, which includes many important emerging biomarkers. Our capabilities are ever-evolving, so if you don’t see your biomarker of interest here, just ask.
| BIOMARKER | TECHNOLOGY | MULTIPLEX |
|---|---|---|
| ALK | IHC | |
| Bcl-2 | IHC | |
| CD30 | IHC | |
| CLDN18 | IHC | |
| c-MET | IHC | |
| c-Myc | IHC | |
| EGFR | PCR | |
| HA (Hyaluronic Acid) | IHC | |
| HER2 | IHC | |
| HER2 Dual ISH | ISH | |
| HER3 | IHC | |
| LIV-1 | IHC | |
| MMR Panel | IHC | |
| p16 | IHC | |
| PD-L1 (SP142) | IHC | |
| PD-L1 (SP263) | IHC | |
| PTEN | IHC | |
| TROP2 | IHC |
Why Digital Pathology?
CDx assays are answering more complex questions than ever before. Our fully integrated uPath solution for digital pathology (DP) delivers new value for patients, bolstering clinical decision-making by allowing pathologists to analyze confidently. Because DP provides additional information that helps to enable precise diagnosis and identify more of your patient population, integration of an algorithm into your strategy stretches your CDx collaboration further.